{
    "id": 29224,
    "fullName": "ETV6 - NTRK1",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "ETV6-NTRK1 results in the fusion of ETV6 and NTRK1 (PMID: 26884591). ETV6-NTRK1 has not been biochemically characterized, but is sensitive to Trk inhibition (PMID: 26884591), and therefore, is predicted to result in a gain of function.",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2120,
        "geneSymbol": "ETV6",
        "terms": [
            "ETV6",
            "TEL",
            "TEL/ABL",
            "THC5"
        ]
    },
    "variant": "ETV6 - NTRK1",
    "createDate": "01/21/2019",
    "updateDate": "01/21/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4914,
                "geneSymbol": "NTRK1",
                "terms": [
                    "NTRK1",
                    "MTC",
                    "p140-TrkA",
                    "TRK",
                    "Trk-A",
                    "TRK1",
                    "TRKA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15722,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ETV6-NTRK1 were sensitive to Rozlytrek (entrectinib) as demonstrated by reduced proliferation relative to cells expressing an empty vector in culture (PMID: 26884591).",
            "molecularProfile": {
                "id": 31178,
                "profileName": "ETV6 - NTRK1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20635,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ETV6-NTRK1 were sensitive to treatment with DS6051b in culture, demonstrating cell growth inhibition (PMID: 31399568).",
            "molecularProfile": {
                "id": 31178,
                "profileName": "ETV6 - NTRK1"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31178,
            "profileName": "ETV6 - NTRK1",
            "profileTreatmentApproaches": [
                {
                    "id": 19328,
                    "name": "Larotrectinib",
                    "profileName": "ETV6 - NTRK1"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}